Scholar Rock Wins FDA Approval for SMA Drug as Psychedelic Therapy Hits Key Milestone

The FDA greenlit Scholar Rock's injectable drug apitegromab (branded as Isembyld) for spinal muscular atrophy, marking a hard-won victory after manufacturing delays. The approval gives patients with the rare muscle-wasting disease a new treatment option that targets the underlying biology of muscle degeneration.

Vital Signs

Key numbers from today's regulatory wins:

• $30 billion — Novartis's market cap evaporation after its neuromuscular candidate del-desiran failed a...